Goldman Sachs’s Titan Pharmaceuticals TTNP Stock Holding History

Goldman Sachs’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-3	Closed	-$55K	–	7191
2016 Q2	$55K	Buy	+3	New	+$63.9K	﹤0.01%	6395

Other funds holding TTNP

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

CWM

Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs's TTNP Position: Q4 2019 in Review

Goldman Sachs sold out of Titan Pharmaceuticals (TTNP) in Q4 2019, closing a stake of 19 shares — an estimated $3K sold.

Goldman Sachs first reported a position in TTNP in Q4 2015 and held it in 7 quarters. The position peaked at $609K in Q3 2016. 21 funds tracked by Wall St. Rank hold TTNP as of Q4 2019.

Goldman Sachs reported no remaining Titan Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Goldman Sachs sold 19 Titan Pharmaceuticals shares in Q4 2019, an estimated $3K.
Goldman Sachs first reported a position in Titan Pharmaceuticals in Q4 2015 and held it in 7 quarters.
Goldman Sachs's Titan Pharmaceuticals position peaked at $609K in Q3 2016.
21 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2019.

Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.